Alzheimer’s disease and other dementias have devastating healthcare, social and economic impacts—and the magnitude of these impacts are increasing as prevalence rapidly rises. The unmet need for new therapies is greater than ever. With a trial failure rate greater than 99%, we must continue to drive new innovations that increase the chance for trial success, including ensuring the most sensitive and reliable endpoints possible.
Cogstate is a leading cognitive science company focused on optimizing the measurement of cognition to guide drug development decision-making. Our solutions have been utilized in more than 90 studies of Alzheimer’s disease, spanning the spectrum of disease stages and in all phases of clinical development.
Download the fact sheet below to learn more about how we support Alzheimer’s disease clinical trials globally.